CARDIFF ONCOLOGY, INC. (CRDF) Total liabilities 2016–2025
CARDIFF ONCOLOGY, INC. (CRDF) total liabilities at each fiscal year-end, per SEC filings.
$16.5MFY2025 · since FY2016: $24.2M → $16.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $16.5M | +15.8% |
| FY2024 | $14.2M | +19.7% |
| FY2023 | $11.9M | +20.8% |
| FY2022 | $9.8M | +7.9% |
| FY2021 | $9.1M | +38.9% |
| FY2020 | $6.6M | +13.7% |
| FY2019 | $5.8M | +41.3% |
| FY2018 | $4.1M | -29.3% |
| FY2017 | $5.8M | -76.1% |
| FY2016 | $24.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CRDF financial trends
CRDF RevenueCRDF Net incomeCRDF Net marginCRDF Gross profitCRDF Gross marginCRDF Operating incomeCRDF Operating marginCRDF Operating cash flowCRDF Free cash flowCRDF Capital expendituresCRDF Return on equityCRDF Stock buybacksCRDF Dividends paidCRDF Total assetsCRDF Shareholders’ equityCRDF overview →